Regencell Bioscience Holdings Ltd. (RGC): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGC Stock Price Chart Interactive Chart >
RGC Price/Volume Stats
| Current price | $38.10 | 52-week high | $59.00 |
| Prev. close | $38.25 | 52-week low | $6.00 |
| Day low | $31.85 | Volume | 2,000 |
| Day high | $38.10 | Avg. volume | 19,079 |
| 50-day MA | $30.91 | Dividend yield | N/A |
| 200-day MA | $27.73 | Market Cap | 481.66M |
Regencell Bioscience Holdings Ltd. (RGC) Company Bio
Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.
Latest RGC News From Around the Web
Below are the latest news stories about Regencell Bioscience Holdings Ltd that investors may wish to consider to help them evaluate RGC as an investment opportunity.
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN NetworkLOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degene |
Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate SymptomsRegencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate. Out of the 37 COVID-19 patients, 36 had all symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period. The trial that after taking RGC-COV19TM, 97.3% of the patients had their mild to moderate COVID-19 symptoms eliminated, save for S |
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy TrialHONG KONG, February 17, 2022--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company") today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach ("EARTH") efficacy trial conducted by Regencell Bioscience Asia Limited ("Regencell Asia") of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). The results have yet to b |
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of DirectorsHONG KONG, December 13, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the |
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEOHONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807. |
RGC Price Returns
| 1-mo | 2.67% |
| 3-mo | 68.58% |
| 6-mo | 18.43% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 19.62% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...